AVB 001
Alternative Names: AVB-001Latest Information Update: 06 Aug 2024
At a glance
- Originator Avenge Bio
- Class Antineoplastics; Cell therapies; Gene therapies; Immunotherapies; Interleukins
- Mechanism of Action Cell replacements; Interleukin 2 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Colorectal cancer; Fallopian tube cancer; Lung cancer; Mesothelioma; Ovarian cancer; Peritoneal cancer
Most Recent Events
- 06 Aug 2024 Discontinued - Phase-I/II for Fallopian tube cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA (Intraperitoneal) (Avenge Bio website, August 2024)
- 06 Aug 2024 Discontinued - Phase-I/II for Ovarian cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Intraperitoneal) (Avenge Bio website, August 2024)
- 06 Aug 2024 Discontinued - Phase-I/II for Peritoneal cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA (Intraperitoneal) (Avenge Bio website, August 2024)